SAGES 2010: Barrett's Esophagus Still a Conundrum for Surgeons

At the recent 12th World Congress of Endoscopic Surgery, hosted by the Society of American Gastrointestinal and Endoscopic Surgeons, physicians discussed the challenges of identifying patients at risk of esophageal cancer. Barrett’s esophagus has long been known as a risk factor, but it remains a mystery as to how to predict which patients with Barrett’s will progress to esophageal cancer and who to screen in order to prevent it,

by Diana Tucker

At the 12th World Congress of Endoscopic Surgery, hosted recently in Washington, DC, by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), physicians discussed the challenges of identifying patients at risk of esophageal cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany

 
• By 

Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By 

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.

Ketryx Wants Its Validated AI Agents To Accelerate Compliance Workflows

 
• By 

While the initial focus is medical devices and life sciences, Ketryx sees future opportunities in other high-regulation sectors including automotive, aerospace and defense, pharma manufacturing and nuclear systems.